Drug Approval | March 25, 2022
Japan approves BMS’ Breyanzi application for relapsed large B-cell lymphoma
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Subscribe To Our Newsletter & Stay Updated